Clinical trials: Avelumab
Ovarian Cancer
Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with…
- Trial name
- NCT03642132
- Testing
- Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Breast Cancer
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
Eligible patients with estrogen receptor positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio.
- Trial name
- ImmunoADAPT (NCT03573648)
- Testing
- Avelumab, Endocrine therapy, Palbociclib
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Tumor, Metastatic Esophageal Squamous Cell Carcinoma
The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
This is a single institutional, single arm, open labeled phase II study to assess the overall radiographic response of adding Avelumab to chemotherapy and palliative radiotherapy in patients with metastatic advanced esophageal…
- Trial name
- NCT03800953
- Testing
- Avelumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
The purpose of this study is to determine if dMMR and/or POLE exonuclease domain mutant stage III colon cancer patients gain clinical benefit (i.e.
- Conditions
- POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer
- Trial name
- POLEM (NCT03827044)
- Testing
- Avelumab
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with melanoma who have progressed on or after chemotherapy and anti-PD-1/PD-L1 therapy.
- Trial name
- NCT03167177
- Testing
- Avelumab, Bevacizumab, Capecitabine
- Sponsor
- ImmunityBio, Inc.
Cancer of Pancreas, Pancreas Cancer
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
Background: Pancreas cancer ranks 4th in all cancer-related deaths in the United States (U.S.) Gemcitabine is a standard treatment for it.
- Conditions
- Cancer of Pancreas, Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT03451773
- Testing
- M7824, Gemcitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
This research is being done because the investigators are looking for new and better ways to treat a type of breast cancer called triple negative breast cancer.
- Trial name
- IMpALA (NCT04188119)
- Testing
- Avelumab, Aspirin, Lansoprazole
- Sponsor
- The Christie NHS Foundation Trust
Leptomeningeal Metastases, Leptomeningeal Disease
Avelumab With Radiotherapy in Patients With Leptomeningeal Disease
This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.
- Trial name
- NCT03719768
- Testing
- Avelumab, Whole Brain Radiotherapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer, Immune System Disorder
Montreal Immune-Related Adverse Events (MIRAE) Study
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in…
- Conditions
- Cancer, Immune System Disorder, Inflammatory Reaction, Autoimmune Diseases
- Trial name
- MIRAE (NCT05139706)
- Where
- Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer
Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study
This is a single arm, open label, phase II study to evaluate the activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced urothelial cancer considered unfit to cisplatin-based chemotherapy, to be…
- Trial name
- ARIES (NCT03891238)
- Testing
- Avelumab
- Where
- 21 sites in Italy
- Volunteers
- 67 people
- Sponsor
- Consorzio Oncotech
Glioblastoma, GBM
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
The purpose of the study is to characterize the safety and tolerability of avelumab in combination with Laser Interstitial Thermal Therapy (LITT) for blood barrier disruption in patients with recurrent glioblastoma.
- Trial name
- NCT03341806
- Testing
- Avelumab, MRI-guided LITT therapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Colon Rectal Cancer
Immunotherapy In Locally Advanced Rectal Cancer
Preoperative CTRT is considered the standard of care in the management of LARC. Preoperative CTRT approach results in significant tumor downstaging and local control with a complete pathological response rate of about 15% even if…
- Trial name
- AVANA (NCT03854799)
- Testing
- Avelumab, Capecitabine, EXTERNAL---BEAM IRRADIATION 50.4 GY
- Where
- Italy
- Volunteers
- 101 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Neoplasms
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02222922
- Testing
- PF-06647020 Q3W, fluconazole, PF-06647020 Q2W
- Where
- 17 sites in United States, Spain
- Volunteers
- 138 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia
Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
The goal of this study is to test the safety of combination treatment with Avelumab and Decitabine in newly diagnosed AML patients who are unfit for intensive induction chemotherapy.
- Trial name
- NCT03395873
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Milton S. Hershey Medical Center
Upper Tract Urothelial Carcinoma
Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC
A Prospective Phase II Study of Adjuvant Cisplatin-Based Chemotherapy followed by Maintenance Avelumab in Upper Tract Urothelial Carcinoma
- Trial name
- NCT07225374
- Testing
- Avelumab 10 mg/kg, Screening, Best Supportive Care (BSC)
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Samsung Medical Center
Pancreatic Cancer
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care first line therapy and chemotherapy.
- Trial name
- NCT03136406
- Testing
- Cyclophosphamide, Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ImmunityBio, Inc.
Breast Cancer
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in…
- Trial name
- PALAVY (NCT04841148)
- Testing
- HCQ, Avelumab, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Breast Cancer
Palbociclib After CDK and Endocrine Therapy (PACE)
This research study is studying three combinations of drugs as treatments for breast cancer. The drugs involved in this study are: Fulvestrant Fulvestrant with Palbociclib Fulvestrant with Palbociclib and Avelumab
- Trial name
- NCT03147287
- Testing
- Palbociclib, Fulvestrant, Avelumab
- Where
- 22 sites in United States
- Volunteers
- 220 people
- Sponsor
- Dana-Farber Cancer Institute
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic